[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Glucagon-like peptide-1 receptor (GLP-1R)-targeted PET imaging with 68Ga-labeled compounds is
able to provide superior sensitivity and specificity to detect insulinoma, like the widely
studied [68Ga]Ga-NOTA-exendin-4. This pilot study was prospectively designed to evaluate the
early dynamic distribution of [68Ga]Ga-HBED-CC-exendin-4, a novel radiopharmaceutical
targeting GLP-1R, which was compared with [68Ga]Ga-NOTA-exendin-4 in the same group of
insulinoma patients.